Portmanteau inhibitor

Today, Portmanteau inhibitor is a topic of great relevance and interest to a wide variety of people. Whether due to its impact on society, its influence on popular culture or its importance in the professional field, Portmanteau inhibitor has become a recurring topic of conversation around the world. With its variety of facets and its ability to generate debate, Portmanteau inhibitor remains an ever-evolving topic that continues to capture the audience's attention and curiosity. In this article, we will explore in detail different aspects of Portmanteau inhibitor, its impact and its relevance today.

A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,[1][2][3] and was further used in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.[4]

Footnotes

  1. ^ "U of M researchers announce advance in treatment of HIV". 25 July 2007. Retrieved 25 July 2007.
  2. ^ "Researchers Discover New Method To Combat HIV". 25 July 2007. Retrieved 25 July 2007.
  3. ^ Zhengqiang Wang; Eric M. Bennett; Daniel J. Wilson; Christine Salomon; Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry. 50 (15): 3416–3419. CiteSeerX 10.1.1.535.8472. doi:10.1021/jm070512p. PMID 17608468.
  4. ^ Bodiwala, H. S.; Sabde, S.; Gupta, P.; Mukherjee, R.; Kumar, R.; Garg, P.; Bhutani, K. K.; Mitra, D.; Singh, I. P. (2011). "Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5". Bioorganic & Medicinal Chemistry. 19 (3): 1256–63. doi:10.1016/j.bmc.2010.12.031. PMID 21227704.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.